Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315Phase 2Active, not recruiting
- Start
- Feb 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and nivolumab in castration-resistant prostate cancer (CRPC). Primary endpoint: Radiographic Progression Free Survival at 6 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
cabozantinibnivolumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05502315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502315.